Switch theme
Sign up to access all valuation multiples
J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the Company are divided into two fields: 1) Chemistry analytical and development services for third parties; 2) Development of the Company’s own line of generic pharmaceuticals.
2020
27
LTM Revenue n/a
LTM EBITDA n/a
$38.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
J. Molner has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, J. Molner achieved revenue of $2.5M and an EBITDA of -$2.1M.
J. Molner expects next 12-month revenue of XXX and NTM EBITDA of XXX
See J. Molner valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.7M | $2.5M | XXX | XXX | XXX |
| Gross Profit | $0.3M | $0.9M | XXX | XXX | XXX |
| Gross Margin | 41% | 38% | XXX | XXX | XXX |
| EBITDA | -$1.0M | -$2.1M | XXX | XXX | XXX |
| EBITDA Margin | -145% | -87% | XXX | XXX | XXX |
| Net Profit | -$0.7M | -$1.2M | XXX | XXX | XXX |
| Net Margin | -100% | -47% | XXX | XXX | XXX |
| Net Debt | $1.3M | $2.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, J. Molner's stock price is EUR n/a (or $n/a).
J. Molner has current market cap of EUR 33.3M (or $35.7M), and EV of EUR 35.4M (or $38.0M).
See J. Molner trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $38.0M | $35.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, J. Molner has market cap of $35.7M and EV of $38.0M.
J. Molner's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate J. Molner's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for J. Molner and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $38.0M | XXX | XXX | XXX |
| EV/Revenue | 15.4x | XXX | XXX | XXX |
| EV/EBITDA | -17.8x | XXX | XXX | XXX |
| P/E | -13.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJ. Molner's NTM/LTM revenue growth is n/a
J. Molner's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, J. Molner's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate J. Molner's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for J. Molner and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 272% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -87% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 122% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 123% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
J. Molner acquired XXX companies to date.
Last acquisition by J. Molner was XXXXXXXX, XXXXX XXXXX XXXXXX . J. Molner acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was J. Molner founded? | J. Molner was founded in 2020. |
| Where is J. Molner headquartered? | J. Molner is headquartered in Estonia. |
| How many employees does J. Molner have? | As of today, J. Molner has 27 employees. |
| Is J. Molner publicy listed? | Yes, J. Molner is a public company listed on TAL. |
| What is the stock symbol of J. Molner? | J. Molner trades under MOLNR ticker. |
| When did J. Molner go public? | J. Molner went public in 2022. |
| Who are competitors of J. Molner? | Similar companies to J. Molner include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of J. Molner? | J. Molner's current market cap is $35.7M |
| What is the current revenue growth of J. Molner? | J. Molner revenue growth between 2023 and 2024 was 272%. |
| Is J. Molner profitable? | Yes, J. Molner is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
